GH Research (GHRS) Competitors $16.75 +0.76 (+4.76%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. MTSR, KYMR, IMVT, MOR, CRNX, ALVO, HCM, AMRX, CPRX, and BHCShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Metsera (MTSR), Kymera Therapeutics (KYMR), Immunovant (IMVT), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Its Competitors Metsera Kymera Therapeutics Immunovant MorphoSys Crinetics Pharmaceuticals Alvotech HUTCHMED Amneal Pharmaceuticals Catalyst Pharmaceuticals Bausch Health Cos GH Research (NASDAQ:GHRS) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability. Do institutionals & insiders have more ownership in GHRS or MTSR? 56.9% of GH Research shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate GHRS or MTSR? GH Research currently has a consensus target price of $32.00, suggesting a potential upside of 91.03%. Metsera has a consensus target price of $55.00, suggesting a potential upside of 26.82%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, GHRS or MTSR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.79-21.20MetseraN/AN/A-$209.13MN/AN/A Is GHRS or MTSR more profitable? Metsera's return on equity of 0.00% beat GH Research's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -19.20% -18.40% Metsera N/A N/A N/A Does the media refer more to GHRS or MTSR? In the previous week, GH Research and GH Research both had 6 articles in the media. Metsera's average media sentiment score of 0.76 beat GH Research's score of 0.35 indicating that Metsera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Metsera 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGH Research beats Metsera on 4 of the 7 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$872.54M$2.92B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-21.2320.4028.6319.71Price / SalesN/A300.36439.46185.19Price / CashN/A43.1536.0257.93Price / Book4.877.748.195.65Net Income-$38.96M-$55.11M$3.24B$257.81M7 Day Performance8.21%0.68%-0.07%0.37%1 Month Performance31.69%8.14%5.52%8.66%1 Year Performance41.12%-2.64%26.39%14.04% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research1.4966 of 5 stars$16.75+4.8%$32.00+91.0%+37.1%$872.54MN/A-21.2310News CoverageAnalyst RevisionMTSRMetseraN/A$28.39-3.6%$55.00+93.7%N/A$3.09BN/A0.0081KYMRKymera Therapeutics2.9354 of 5 stars$43.81-2.2%$59.11+34.9%-0.2%$2.92B$47.07M-14.13170IMVTImmunovant1.3561 of 5 stars$16.42-3.1%$38.33+133.5%-42.7%$2.90BN/A-5.99120MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.4367 of 5 stars$29.06-2.5%$71.75+146.9%-41.2%$2.79B$1.04M-7.61210ALVOAlvotech3.4008 of 5 stars$9.02-1.8%$18.00+99.6%-30.5%$2.77B$491.98M24.381,032HCMHUTCHMED1.6126 of 5 stars$15.42-2.5%$19.00+23.2%-11.4%$2.76B$630.20M0.001,811Positive NewsAMRXAmneal Pharmaceuticals2.5657 of 5 stars$8.41-0.1%$11.60+37.9%+12.1%$2.64B$2.79B-210.208,100CPRXCatalyst Pharmaceuticals4.8952 of 5 stars$20.95-2.4%$32.83+56.7%+25.1%$2.62B$491.73M13.3480Positive NewsBHCBausch Health Cos3.7697 of 5 stars$6.88-2.5%$7.42+7.8%-12.4%$2.61B$9.63B-62.5520,700 Related Companies and Tools Related Companies Metsera Alternatives Kymera Therapeutics Alternatives Immunovant Alternatives MorphoSys Alternatives Crinetics Pharmaceuticals Alternatives Alvotech Alternatives HUTCHMED Alternatives Amneal Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Bausch Health Cos Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GHRS Stock Alerts